Y-Intercept (HK)’s CRISPR Therapeutics CRSP Stock Holding History

Y-Intercept (HK)’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-39,161	Closed	-$1.9M	–	1645
2025 Q2	$1.9M	Buy	+39,161	New	+$1.52M	0.05%	627
2021 Q3	–	Sell	-3,716	Closed	-$602K	–	692
2021 Q2	$602K	Sell	3,716 -3,732	-50%	-$454K	0.15%	216
2021 Q1	$858K	Buy	+7,448	New	+$1.12M	0.23%	128

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Y-Intercept (HK)'s CRSP Position: Q3 2025 in Review

Y-Intercept (HK) sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 39,161 shares — an estimated $1.9M sold.

Y-Intercept (HK) first reported a position in CRSP in Q1 2021 and held it in 3 quarters. The position peaked at $1.9M in Q2 2025. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

Y-Intercept (HK) reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 39,161 CRISPR Therapeutics shares in Q3 2025, an estimated $1.9M.
Y-Intercept (HK) first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 3 quarters.
Y-Intercept (HK)'s CRISPR Therapeutics position peaked at $1.9M in Q2 2025.
440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.